AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.17 which represents a decrease of $-3.33 or -1.87% from the prior close of $178.5. The stock opened at $176.86 and touched a low of ...

Under the terms of the agreement, AbCellera will lead discovery activities and AbbVie has the right to develop and ...

Czech National Bank increased its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 6.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...

This was the stock's second consecutive day of losses.

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...

SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group ...

The stock's fall snapped a three-day winning streak.